Posted: February 21, 2008

CombiMatrix Corporation to Release Fourth Quarter Financial Results On March 6

(Nanowerk News) CombiMatrix Corporation (Nasdaq:CBMX) announced today that it will release its fourth quarter and year end financial results on Thursday, March 6, 2008. Results will be released at the close of trading on that day.
The announcement released earlier today by its former parent company, Acacia Research Corporation, regarding Acacia's earnings release has been erroneously reported by some news agencies as a CombiMatrix Corporation earnings announcement.
A conference call has also been scheduled regarding CombiMatrix Corporation's fourth quarter and year end earnings announcement. The presentation and Q&A session will start at 1:30 p.m. Pacific Time (4:30 p.m. Eastern) on Thursday, March 6, 2008.
To listen to the presentation by phone, dial 1-800-704-9804 for domestic callers, and 1-404-920-6604 for direct dial or international callers. All callers will need to provide the participant code 329443# (329443 followed by the # key). A replay of the audio presentation will be available for 14 days using the same dial-in numbers, but the participant code for the recorded playback is 641376# (641376 followed by the # key).
The call will be webcast live and can be accessed at CombiMatrix's website at, in the Investor section.
About CombiMatrix Corporation
CombiMatrix Corporation is a diversified biotechnology business having its focus on the development of proprietary technologies, products and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology research, defense and homeland security markets, as well as other potential markets where our products and services could be utilized. The technologies we have developed include a platform technology to rapidly produce customizable, in-situ synthesized, oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations and proteins. This technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology. Other technologies include proprietary molecular synthesis and screening methods for the discovery of potential new drugs. CombiMatrix Molecular Diagnostics, Inc. ("CMDX"), a wholly owned subsidiary of the Company located in Irvine, California, has developed capabilities of producing arrays that utilize bacterial artificial chromosomes, which also enable genetic analysis.
Source: CombiMatrix Corporation
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: